Bogart Wealth LLC’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$41.6K Buy
868
+27
+3% +$1.16K ﹤0.01% 587
2026
Q1
$30.9K Hold
841
﹤0.01% 613
2025
Q4
$42.8K Sell
841
-261
-24% -$13.3K ﹤0.01% 513
2025
Q3
$61.1K Buy
1,102
+245
+29% +$14.3K ﹤0.01% 414
2025
Q2
$59.1K Sell
857
-85
-9% -$5.78K ﹤0.01% 415
2025
Q1
$65.4K Buy
942
+4
+0.4% +$330 ﹤0.01% 368
2024
Q4
$80.7K Sell
938
-304
-24% -$32.9K ﹤0.01% 333
2024
Q3
$148K Buy
1,242
+18
+1% +$2.4K 0.01% 251
2024
Q2
$175K Buy
1,224
+210
+21% +$27.8K 0.01% 221
2024
Q1
$130K Buy
1,014
+22
+2% +$2.62K 0.01% 241
2023
Q4
$103K Hold
992
0.01% 267
2023
Q3
$90.2K Hold
992
0.01% 264
2023
Q2
$80.3K Hold
992
0.01% 266
2023
Q1
$78.9K Buy
992
+512
+107% +$36.3K 0.01% 253
2022
Q4
$32.5K Buy
480
+8
+2% +$469 ﹤0.01% 363
2022
Q3
$24K Hold
472
﹤0.01% 403
2022
Q2
$26K Hold
472
﹤0.01% 382
2022
Q1
$26K Hold
472
﹤0.01% 351
2021
Q4
$26K Buy
472
+154
+48% +$8.34K ﹤0.01% 337
2021
Q3
$15K Hold
318
﹤0.01% 400
2021
Q2
$13K Hold
318
﹤0.01% 410
2021
Q1
$11K Buy
+318
New +$11.3K ﹤0.01% 407

Other funds holding NVO

Bogart Wealth LLC's NVO Position: Q2 2026 in Review

Bogart Wealth LLC increased its Novo Nordisk (NVO) stake by 3.2% in Q2 2026, buying an estimated $1.16K and bringing the position to 868 shares worth $41.6K. The position accounts for ﹤0.01% of the portfolio, ranked #587.

Bogart Wealth LLC first reported a position in NVO in Q1 2021 and has held it in 22 quarters since. The position peaked at $175K in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Bogart Wealth LLC held 868 shares of Novo Nordisk worth $41.6K as of Q2 2026.
  • Bogart Wealth LLC bought 27 Novo Nordisk shares in Q2 2026, an estimated $1.16K.
  • Novo Nordisk made up ﹤0.01% of Bogart Wealth LLC's portfolio in Q2 2026, its #587 holding.
  • Bogart Wealth LLC first reported a position in Novo Nordisk in Q1 2021 and has held it in 22 quarters since.
  • Bogart Wealth LLC's Novo Nordisk position peaked at $175K in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Bogart Wealth LLC's 13F filing for Q2 2026, filed 24 Jul 2026.